Might you soon take a skin cell from a patient with retinitis pigmentosa, roll it back to a pluripotent state, culture it to become retinal cells and trial gene therapy on it in vitro?

Is the potential dystopia that is myopia a consequence of too much study?

Population-level disease prophylaxis with statins has improved the lives of millions. But there has been some protest about this mass medication. Is the next battle not with disease, but with the press?

What does analysis of the last five years of the literature on keratoconus tell us about the priorities of the field and the major contributors to it?

A head-mounted iPhone-based ophthalmoscope is the latest step in the rapidly evolving world of smartphone fundoscopy

In August, The Ophthalmologist will publish a special issue showcasing the very best images from the field of ophthalmology.

Valeant and Allergan continue to joust, Santen purchases MSD’s ophthalmology drug portfolio in selected markets, and Kala completes a US$22.5 million Series B financing round

Purchase of the ex-US rights for Fovista is costing Novartis US$200 million down and up to a cool US$1 billion in milestone payments

Common yoga positions significantly raise IOP for prolonged periods

The body’s own regulatory T-lymphocytes, known as Tregs, can be taught to douse inflammation.